{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:43:42Z","timestamp":1791636222966,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.msard.2025.106400","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T01:25:03Z","timestamp":1742606703000},"page":"106400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8692-6936","authenticated-orcid":false,"given":"Maria Therese","family":"Fossum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde Marie","family":"Torgauten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Harald","family":"Aarseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shirzadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Wergeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"B\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Wesnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2025.106400_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.msard.2025.106400_bib0012","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00415-021-10399-8","article-title":"Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis","volume":"268","author":"Boremalm","year":"2021","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.msard.2025.106400_bib0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585231208311","article-title":"Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity","volume":"30","author":"Bou Rjeily","year":"2024","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.msard.2025.106400_bib0014","article-title":"Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?","volume":"10","author":"Claverie","year":"2023","journal-title":"Neurology: neuroimmunology & neuroinflammation"},{"issue":"3","key":"10.1016\/j.msard.2025.106400_bib0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.msard.2025.106400_bib0028","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1111\/ene.15891","article-title":"Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience","volume":"30","author":"Guerrieri","year":"2023","journal-title":"European Journal of Neurology"},{"issue":"7","key":"10.1016\/j.msard.2025.106400_bib0024","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(17)30158-8","article-title":"Gadolinium deposition in the brain: summary of evidence and recommendations","volume":"16","author":"Gulani","year":"2017","journal-title":"The Lancet Neurology"},{"issue":"7","key":"10.1016\/j.msard.2025.106400_bib0004","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.msard.2025.106400_bib0003","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2025.106400_bib0009","unstructured":"Jan Harald Aarseth TS, Anne Britt Sk\u00e5r, H\u00e5vard Henriksen, Stig Wergeland. Norwegian Multiple Sclerosis Registry and biobank- annual report 2023. www.kvalitetsregistre.no: Helse Bergen, Haukeland Universitetssjukehus 15.06.24."},{"key":"10.1016\/j.msard.2025.106400_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101468","article-title":"Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity","volume":"37","author":"Juto","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106400_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104556","article-title":"Predictors of hospitalization due to infection in rituximab-treated MS patients","volume":"71","author":"Karlowicz","year":"2023","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"3","key":"10.1016\/j.msard.2025.106400_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.msard.2025.106400_bib0013","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"199","key":"10.1016\/j.msard.2025.106400_bib0023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ane.12427","article-title":"The Norwegian Multiple Sclerosis Registry and Biobank","volume":"132","author":"Myhr","year":"2015","journal-title":"Acta Neurol Scand"},{"issue":"23","key":"10.1016\/j.msard.2025.106400_bib0002","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/WNL.0b013e3181e24373","article-title":"Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial","volume":"74","author":"Naismith","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106400_bib0010","unstructured":"National Treatment Guideline for Multiple Sclerosis in Norway: The Norwegian Directorate of Health; 2024 [updated 30-April-2024]. Available from: https:\/\/www.helsebiblioteket.no\/innhold\/nasjonal-faglig-retningslinje\/multippel-sklerose."},{"key":"10.1016\/j.msard.2025.106400_bib0022","unstructured":"Nel, Nevro, 2021. Treatment guideline for neurological diseases: Rituximab. Norwegian association of Neurology [updated 26. feb 2021]. Available from https:\/\/nevrologi.legehandboka.no\/handboken\/behandlinger\/behandlingsopplegg\/medikamenter\/rituximab-mabthera-ved-ms."},{"issue":"1","key":"10.1016\/j.msard.2025.106400_bib0016","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1212\/NXI.0000000000001115","article-title":"Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab","volume":"9","author":"Perriguey","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2025.106400_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106400_bib0001","article-title":"Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis","volume":"11","author":"Roach","year":"2020","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.msard.2025.106400_bib0027","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1016\/j.msard.2025.106400_bib0026","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurology"},{"issue":"20","key":"10.1016\/j.msard.2025.106400_bib0006","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106400_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200056","article-title":"Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis","volume":"10","author":"Starvaggi Cucuzza","year":"2023","journal-title":"Neurology - Neuroimmunology Neuroinflammation"},{"issue":"8","key":"10.1016\/j.msard.2025.106400_bib0005","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2025.106400_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103364","article-title":"The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis","volume":"57","author":"Toorop","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2025.106400_bib0008","article-title":"Torkildsen O. Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - A cohort study","volume":"7","author":"Torgauten","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"12","key":"10.1016\/j.msard.2025.106400_bib0021","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/jnnp-2023-333206","article-title":"Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study","volume":"95","author":"Virtanen","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2025.106400_bib0018","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:26:36Z","timestamp":1746620796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825001427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"alternative-id":["S2211034825001427"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106400","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106400"}}